Testosterone-topical fortigel - cellegy: fortigel, tostrex.
Cellegy Pharmaceuticals in the US is developing a topical gel formulation of testosterone replacement therapy [Tostrex, Fortigel] for men, based on the company's proprietary Permeate technology. The new gel formulation, containing 2% testosterone, is intended to be a more convenient alternative to injectable testosterone, and is designed to reduce the skin irritation associated with currently available dermal patch products. Fortigel (previously known as Tostrex Gel) will be provided in a proprietary metered dose canister. Fortigel is engineered to deliver physiological levels of testosterone in an easy-to-use, non-greasy, non-staining topical formulation, which is designed for discreet application to the inner thigh.A similar product is also being developed for women. In April 2003, following a request by the US FDA, Cellegy changed the trade name of its topical gel formulation of testosterone from Tostrex Gel to Fortigel. The name change was made in response to the US FDA's observation that the original name could potentially create confusion on the part of medical professionals and consumers when compared with currently marketed products. Cellegy have submitted a European Marketing Authorization Application (MAA) for Fortigel as a treatment for male hormone replacement therapy or hypogonadism. Sweden is acting as the reference member state for the Mutual Recognition Procedure. Data presented at the 98th Annual Meeting of the American Urological Association have shown that the topical testosterone gel restored serum testosterone levels to within the physiological range in 92% of hypogonadal men who completed the trial. Cellegy is considering outlicencing possibilities for the product outside the US. Fortigel is covered by an issued patent in the US and patents are pending in other markets. In April 2001, Cellegy estimated the US market size for products such as Tostrex to be $US5 billion; approximately 5 million men are affected by male hypogonadism in the US.
D000279:Administration, Cutaneous; D000328:Adult; D000368:Aged; D005782:Gels; D006801:Humans; D007006:Hypogonadism / Q000097:blood / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D013678:Technology, Pharmaceutical / Q000379:methods; D009626:Terminology as Topic; D013739:Testosterone / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
D005782:Gels; D013739:Testosterone